학술논문
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
Document Type
Article
Author
Source
In: Therapeutic Advances in Gastroenterology . (Therapeutic Advances in Gastroenterology, January-December 2022, 15)
Subject
Language
English
ISSN
17562848
1756283X
1756283X